Emily R. Trunnell

Emily R. Trunnell

Auto-generated profile, based on publicly available information

Emily R. Trunnell

People for the Ethical Treatment of Animals

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Drug Discovery Today
Verified
Journal Article
Closed access
ETEmily R. Trunnell
Emily R. Trunnell
CCConstança Carvalho
Constança Carvalho

27 June 2024 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
ETEmily R. Trunnell
Emily R. Trunnell
JBJulia Baines
Julia Baines
SFStephen Farghali
Stephen Farghali
TJTara Jackson
Tara Jackson
KJKimberley Jayne
Kimberley Jayne
TSTina Stibbe
Tina Stibbe
Depressive disorders are one of the most common mental disorders globally and progress in treating these disorders has been hampered, in part, by a lack of suitable nonclinical efficacy tests. Two common tests used in nonclinical efficacy studies of antidepressants-the forced swim test (FST) and tail suspension test (TST)-have come under criticism in recent years for their inconsistency and lack of validity, yet they continue to be used in the pharmaceutical industry. In this review, we provide a rationale for why international pharmaceutical regulatory and guidance agencies should begin issuing direction on methods for non-clinical efficacy testing that traditionally use the FST and TST, particularly considering that some regulators, such as those in the U.S. and E.U., allow the authorization of clinical trials to proceed without requiring tests in animals. The area of antidepressant drug discovery represents an important opportunity for reducing the attrition of psychiatric drugs, harmonizing regulatory requirements, and reducing animal use. Specific recommendations for the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) have been provided.

30 August 2023 in Advanced Science
Verified
Journal Article
Open access
CKCatharine E. Krebs
Catharine E. Krebs
CCCelean Camp
Celean Camp
HCHelder Constantino
Helder Constantino
Lilas CourtotLilas Courtot
Lilas Courtot
Owen KavanaghOwen Kavanagh
Owen Kavanagh
ETEmily R. Trunnell
Emily R. Trunnell
There is growing recognition that animal methods bias, a preference for animal‐based methods where they are not necessary or where nonanimal‐based methods may already be suitable, can impact the likelihood or timeliness of a manuscript being accepted for publication. Following April 2022 workshop about animal methods bias in scientific publishing, a coalition of scientists and advocates formed a Coalition to Illuminate and Address Animal Methods Bias (COLAAB). The COLAAB has developed this guide to be used by authors who use nonanimal methods to avoid and respond to animal methods bias from manuscript reviewers. It contains information that researchers may use during 1) study design, including how to find and select appropriate nonanimal methods and preregister a research plan, 2) manuscript preparation and submission, including tips for discussing methods and choosing journals and reviewers that may be more receptive to nonanimal methods, and 3) the peer review process, providing suggested language and literature to aid authors in responding to biased reviews. The author's guide for addressing animal methods bias in publishing is a living resource also available online at animalmethodsbias.org, which aims to help ensure fair dissemination of research that uses nonanimal methods and prevent unnecessary experiments on animals.

22 December 2024 in NAM Journal
Verified
Journal Article
Closed access
CKCatharine E. Krebs
Catharine E. Krebs
SGSven Geissler
Sven Geissler
Kathrin HerrmannKathrin Herrmann
Kathrin Herrmann
KKKenneth Kandaras
Kenneth Kandaras
Owen KavanaghOwen Kavanagh
Owen Kavanagh
ETEmily R. Trunnell
Emily R. Trunnell

1 September 2019 in Brain Stimulation
Verified
Journal Article
Closed access
ETEmily R. Trunnell
Emily R. Trunnell

16 October 2018 in Journal of Medicinal Food
Verified
Journal Article
Closed access
SASuresh Ambati
Suresh Ambati
CMColette Miller
Colette Miller
EBErica F. Bass
Erica F. Bass
NHNatalie M. Hohos
Natalie M. Hohos
DHDiane L. Hartzell
Diane L. Hartzell
SRSrujana Rayalam
Srujana Rayalam
Menopause induces a loss of bone as a result of estrogen deficiency. Despite pharmaceutical options for the treatment of osteopenia and osteoporosis, many aging women use dietary supplements with estrogenic activity to prevent bone loss and other menopausal-related symptoms. Such supplements are yet to be tested for efficacy against a Food and Drug Administration (FDA) approved medication for menopausal bone loss such as zoledronic acid (ZA). The postmenopausal rat model was used to investigate the efficacy of various synergistic phytochemical blends mixed into the diet for 16 weeks. Retired-breeder, Fischer 344 rats were randomly assigned to sham or ovariectomy surgery and 4 treatment groups: ZA; genistein supplementation; and a low dose and high dose blend of genistein, resveratrol, and quercetin. Ovariectomy resulted in a loss of both trabecular and cortical bone which was prevented with ZA. The phytochemical blends tested were unable to reverse these losses. Despite the lack of effectiveness in preventing bone loss, a significant dose–response trend was observed in the phytochemical-rich diets in bone adipocyte number compared to ovariectomized control rats. Data from this study indicate that estrogenic phytochemicals are not as efficacious as ZA in preventing menopausal-related bone loss but may have beneficial effects on bone marrow adiposity in rats.